Absci Balance Sheet Health
Financial Health criteria checks 5/6
Absci has a total shareholder equity of $176.2M and total debt of $7.9M, which brings its debt-to-equity ratio to 4.5%. Its total assets and total liabilities are $217.3M and $41.1M respectively.
Key information
4.5%
Debt to equity ratio
US$7.92m
Debt
Interest coverage ratio | n/a |
Cash | US$97.66m |
Equity | US$176.18m |
Total liabilities | US$41.12m |
Total assets | US$217.30m |
Recent financial health updates
No updates
Recent updates
Absci: Differentiated Antibody Discovery Play
Feb 27Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M
Aug 11Absci teams up to help develop antibody drugs for cancer
Jul 07Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out
Jan 10IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)
Jul 22Financial Position Analysis
Short Term Liabilities: ABSI's short term assets ($120.6M) exceed its short term liabilities ($29.6M).
Long Term Liabilities: ABSI's short term assets ($120.6M) exceed its long term liabilities ($11.6M).
Debt to Equity History and Analysis
Debt Level: ABSI has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ABSI's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABSI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ABSI is forecast to have sufficient cash runway for 12 months based on free cash flow estimates, but has since raised additional capital.